title: Targeting the NF-κB pathway in cancer therapy.
abstract: Most NF-κB inhibitors target the IKK complex, IκB proteins, or NF-κB transcription factors. The most promising classes of inhibitors include antioxidants, antiinflammatory compounds, natural compounds, statins, proteasome inhibitors, IKKβ inhibitors, biologics, gene therapy, and RNA interference. Targeting NF-κB is limited by intrinsic pathway complexity, cross-talk with other pathways, a lack of biomarkers, poor drug specificity, drug resistance, and difficulty with drug delivery. Future NF-κB targeting will be improved through better understanding of the pathway, more specific inhibitors, and multimodality therapies.
authors.affiliation: Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Erstad
authors.forename: James C
authors.initials: JC
authors.lastname: Cusack
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D016328:NF-kappa B
keywords: Apoptosis; Chemoresistance; IKK inhibitor; NF-κB inhibitor; Radioresistance; Targeting NF-κB